Drugs Made In America Acquisition Corp. Units (DMAAU) — Financial Flexibility Index

Latest as of March 2026: -0.02x

Drugs Made In America Acquisition Corp. Units (DMAAU) has a Financial Flexibility Index of -0.02x as of March 2026. Free cash flow of $-125.18K (operating CF $-125.18K minus capex $0.00) represents 0% of total liabilities ($7.28 Million). Check cash flow reinvestment rate of Drugs Made In America Acquisition Corp. to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

-0.02x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-125.18K
Operating CF − Capex

Total Liabilities

$7.28 Million
USD

Capital Expenditures

$0.00
USD

Drugs Made In America Acquisition Corp. Units Financial Flexibility Index (2024–2025)

Historical Financial Flexibility Index trend for Drugs Made In America Acquisition Corp. Units across 2 annual periods. For the full cash flow conversion analysis, see Drugs Made In America Acquisition Corp. operating cash flow efficiency.

Annual Financial Flexibility Index for Drugs Made In America Acquisition Corp. Units (2024–2025)

Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition Corp. Units. Explore Drugs Made In America Acquisition Corp. (DMAAU) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -0.07x $-539.19K $-539.19K $7.28 Million ▲ +100.0%
2024 -216.50x $-172.26K $-172.26K $795.67
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities